Entropy Neurodynamics Limited (ASX: EX1)
Health Care · Pharmaceuticals · AU
AU$—
— today · — 1Y
Entropy Neurodynamics Limited (ASX: EX1) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $41.65M and employs 50 people.
Tweenvest scores Entropy Neurodynamics Limited across four factors: quality 26/100. Its strongest factor is quality.
EX1 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $41.65M
- Revenue (TTM)
- $1.06M
- P/E
- —
- EPS
- -0.01
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- AU$—
- 52-week low
- AU$—
- Avg volume (3M)
- —
- Shares outstanding
- 1.63B
- Employees
- 50
- Next earnings
- —
About Entropy Neurodynamics Limited
Exopharm Limited is an Australian clinical-stage firm dedicated to developing groundbreaking therapeutics utilizing extracellular vesicles (EVs). Its core technologies include an extracellular vesicle positioning system (EVPS), which facilitates the precise targeting of exosomes by attaching specific molecules to their surface, guiding them to particular tissues or cell types. Another innovation is oligonucleotide packing, designed to optimize therapeutic delivery by preferentially loading specific RNA molecules into exosomes as medicinal cargo. Additionally, Exopharm employs ligand-based exosome affinity purification for effectively isolating and refining exosomes from biological fluids such as blood and cell culture media. The company's engineered EV product portfolio features Fortrexo CoV, aimed at treating SARS-CoV-2 infections; Cognevo, developed for neurodegenerative diseases; and PlexoDox, intended for cancer treatment. Exopharm Limited also maintains a research collaboration with Showa Denko Materials Co., Ltd. The company was founded in 2013 and is headquartered in Melbourne, Australia.
- ISIN
- AU0000030975
- Founded
- 2019
- Listed since
- Dec 17, 2018
- Exchange
- Australian Securities Exchange
- Currency
- AUD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,233.66 | -1.06% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $273.14 | +0.04% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $156.45 | +3.84% |
| Roche Holding AGSWX: ROP | $371.62B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.57 | +2.15% |
Figures last refreshed May 2, 2024.